Anteris Technologies Global (NASDAQ:AVR) rose 7.19% on June 23, 2026, as optimism around the Medtronic partnership supported the valve pipeline, with shares closing at $10.28.

Key Highlights

  • Rose 7.19%: Anteris Technologies Global closed at $10.28 on June 23 after moving $0.69 per share.
  • Catalyst: During the session, optimism around the Medtronic partnership supported the valve pipeline.
  • Company: Anteris Technologies Global develops transcatheter heart valve systems for patients with structural heart disease.
  • Session: The stock finished at $10.28, while the available company record showed a disclosed catalyst for the move.

Anteris Technologies Global (NASDAQ:AVR) rose 7.19% on June 23, 2026, closing at $10.28 after a $0.69 per-share move. The session’s advance came as optimism around the Medtronic partnership supported the valve pipeline, based on the available company disclosures and trading context.

Investor attention remained focused on Anteris's DurAVR transcatheter aortic valve replacement pipeline and its previously disclosed strategic relationship with Medtronic. The Medtronic collaboration, which provides access to distribution and commercial infrastructure, has been a sustained re-rating catalyst for the stock since the agreement was announced.

Anteris Technologies Global develops transcatheter heart valve systems for patients with structural heart disease.

No additional clinical data or regulatory filing was made on the session. The gain reflected carry-forward optimism from that partnership.

The update concerned the development or regulatory path of a healthcare programme rather than a completed commercial launch. Clinical-stage milestones can include agency feedback, trial design, patient data or filing plans, each of which carries a different level of regulatory significance.

The shares closed at $10.28 after the market incorporated the disclosed programme information. The available record showed no additional approval decision during the June 23 session unless specifically stated in the company update.

For the June 23 close, the defining facts were the 7.19% advance, the $10.28 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.